Indefinite Delivery Contract SPE2DR25D9631

Award Date 8/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, provides a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 single-award IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic prescription...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to various Department of Defense (DoD) customers worldwide. The contract, valued at $499,999,999, has a base period of 30 months and three 30-month option periods, allowing the DLA to issue firm fixed-price delivery orders for branded...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to support the medical needs of Department of Defense (DoD) healthcare facilities worldwide. The IDC, valued at $499,999,999 and valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The $499,999,999 contract, valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of branded and generic...
This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $499,999,999 single-award IDC enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities...
The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, which runs through November 2026, covers a wide range of pharmaceutical products to support the medical supply needs of military health facilities worldwide, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 single-award contract covers a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers...
The Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to support the medical needs of Department of Defense (DoD) healthcare facilities worldwide. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic...
The Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business, for the provision of a comprehensive range of pharmaceutical products and medical supplies. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the medical supply...
The Indefinite Delivery Contract (IDC) award to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) aims to establish a single-award, Firm Fixed Price contract to provide a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. The $499,999,999 IDC, valid through November 2026, encompasses branded and generic prescription drugs, over-the-counter medications, biologics, and...

This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $499,999,999, covers the delivery of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the medical supply needs of military health facilities worldwide.

The contract was awarded under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, which aims to establish Prime Vendor Contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, Department of Defense, United States Coast Guard, and U.S. Naval Fleet. The contract has a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. The solicitation was an unrestricted, fully competitive acquisition, with the intent to make multiple awards for separate regions to ensure resilience and access to vital pharmaceuticals during contingencies or natural disasters.

Generated 6/6/25, 9:42 AM